Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model.

abstract：:Antibodies can be used to target cancer therapies to malignant tissue; the approach is attractive because conventional treatments such as chemo- and radiotherapy are dose limited due to toxicity in normal tissues. Effective targeting relies on appropriate pharmacokinetics of antibody-based therapeutics, ideally showin...

journal_title：Cancer chemotherapy and pharmacology

authors： Chester KA,Mayer A,Bhatia J,Robson L,Spencer DI,Cooke SP,Flynn AA,Sharma SK,Boxer G,Pedley RB,Begent RH

更新日期：2000-01-01 00:00:00

abstract：:We conducted a double-blind, randomized crossover study to compare the toxicity and antiemetic efficacy of the 5-hydroxytryptamine3 receptor antagonist batanopride with that of metoclopramide in 21 chemotherapy-naive patients receiving at least 70 mg/m2 cisplatin. The study was terminated when hypotension was observed...

journal_title：Cancer chemotherapy and pharmacology

authors： Fleming GF,Vokes EE,McEvilly JM,Janisch L,Francher D,Smaldone L

更新日期：1991-01-01 00:00:00

abstract：:Paclitaxel is used as a single agent, and in combination with other drugs, as a standard of care in the treatment of squamous cell carcinoma of the head and neck (SCCHN). However, the use of paclitaxel for therapy of SCCHN may be accompanied by serious side effects. Paclitaxel is a known cytotoxic inhibitor of cell pr...

journal_title：Cancer chemotherapy and pharmacology

authors： Jaglowski JR,Zagon IS,Stack BC Jr,Verderame MF,Leure-duPree AE,Manning JD,McLaughlin PJ

更新日期：2005-07-01 00:00:00

abstract：:Purified human leukocyte interferon produced by recombinant techniques (IFN-alpha A) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents a...

journal_title：Cancer chemotherapy and pharmacology

authors： Aapro MS,Alberts DS,Salmon SE

更新日期：1983-01-01 00:00:00

abstract：PURPOSE:To differentiate the antagonistic and agonistic effect of toremifene at the level of the hypothalamus-hypophysis axis a leutinizing hormone-releasing hormone (LHRH) test was performed during a phase II clinical trial. METHODS:In 15 postmenopausal patients with advanced breast cancer, follicle-stimulating hormo...

journal_title：Cancer chemotherapy and pharmacology

authors： Számel I,Hindy I,Budai B,Kangas L,Hajba A,Lammintausta R

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:Polyamines are biologic cations necessary for normal cell growth. Polyamine analogues have been shown to be effective inhibitors of tumor growth. We tested the effect of the polyamine analogues 1,1 9-bis(ethylamino)-5,10,15-triazanonadecane (BE-4-4-4-4), N1,N11-bis(ethyl)norspermine (BE-3-3-3) and 1,15-bis(ethy...

journal_title：Cancer chemotherapy and pharmacology

authors： Jeffers L,Church D,Basu H,Marton L,Wilding G

更新日期：1997-01-01 00:00:00

abstract：:Melphalan (L-PAM) pharmacokinetics were investigated in nine ovarian cancer patients before and after cisplatin (DDP) treatment. When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46.4 +/- 6.7 min, 20.5...

journal_title：Cancer chemotherapy and pharmacology

authors： Zucchetti M,D'Incalci M,Willems Y,Cavalli F,Sessa C

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:To gain a better understanding of the impact of postprogression survival (PPS) and post-trial anticancer therapy on overall survival (OS) in first-line pancreatic cancer patients. METHODS:A literature search identified 54 randomized trials, focusing on gemcitabine monotherapy to eliminate effects of heterogene...

journal_title：Cancer chemotherapy and pharmacology

authors： Kasuga A,Hamamoto Y,Takeuchi A,Kawasaki K,Suzuki T,Hirata K,Sukawa Y,Takaishi H,Kanai T

更新日期：2017-03-01 00:00:00

abstract：PURPOSE:Some clinical studies on etoposide (Eto) have shown marked schedule dependency of the effect (starting at about 1 mg/l) and toxicity (over about 10 mg/l) whereas other studies have not confirmed these results. What are the conclusions we can draw from these inconsistent results when developing new low-dose (LD)...

journal_title：Cancer chemotherapy and pharmacology

authors： Würthwein G,Boos J

更新日期：2002-04-01 00:00:00

abstract：PURPOSE:Tetrandrine (Tet), a bis-benzylisoquinoline alkaloid that was isolated from the dried root of Hang-Fang-Chi (Stephania tetrandra S. Moore), is well known as processing a marked antitumor effect in vitro and in vivo. The aim of this study was to assess the interaction between tetrandrine and chemotherapeutic age...

journal_title：Cancer chemotherapy and pharmacology

authors： Wei J,Liu B,Wang L,Qian X,Ding Y,Yu L

更新日期：2007-10-01 00:00:00

abstract：PURPOSE:The study was undertaken to determine the metabolism of dexrazoxane (ICRF-187) to its one-ring open hydrolysis products and its two-rings opened metal-chelating product ADR-925 in cancer patients with brain metastases treated with high-dose etoposide. In this phase I/II trial dexrazoxane was used as a rescue ag...

journal_title：Cancer chemotherapy and pharmacology

authors： Schroeder PE,Jensen PB,Sehested M,Hofland KF,Langer SW,Hasinoff BB

更新日期：2003-08-01 00:00:00

abstract：:Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the conversion of ribonucleotides into deoxyribonucleotides. However, nowadays the main focus has shifted to structurally similar hydroxamic...

journal_title：Cancer chemotherapy and pharmacology

authors： Saban N,Bujak M

更新日期：2009-07-01 00:00:00

abstract：OBJECTIVES:The aim of this phase II study was to evaluate the response rate to gemcitabine combined with cisplatin in patients with locally advanced, metastatic or recurrent biliary tract cancer who had received no prior chemotherapy. METHODS:The treatment consisted of cisplatin 70 mg/m(2) in intravenous infusion foll...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee J,Kim TY,Lee MA,Ahn MJ,Kim HK,Lim HY,Lee NS,Park BJ,Kim JS,Korean Cancer Study Group.

更新日期：2008-01-01 00:00:00

abstract：PURPOSE:The aim of this study is to examine the factors affecting sensitivity to cisplatin, carboplatin, and oxaliplatin in human colorectal tumor cell lines. METHODS:Caco-2, DLD-1, HCT-15, HCT116, LS180, SW620, and WiDr cells were used. Their growth inhibition by platinum derivatives was evaluated with a WST-1 assay ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kitada N,Takara K,Minegaki T,Itoh C,Tsujimoto M,Sakaeda T,Yokoyama T

更新日期：2008-09-01 00:00:00

abstract：PURPOSE:We assessed the clinical efficacy and safety of mitoxantrone hydrochloride which has been used as an anticancer drug in our hospital to treat breast cancer patients since 1993. METHODS:A group of 23 patients with breast cancer were given one course of the following regimen every 3 weeks: mitoxantrone hydrochlo...

journal_title：Cancer chemotherapy and pharmacology

authors： Katsumata K,Tomioka H,Kusama M,Aoki T,Koyanagi Y

更新日期：2003-07-01 00:00:00

abstract：PURPOSE:Although cisplatin is an important agent in non-small-cell lung cancer (NSCLC), de novo resistance is common and acquired resistance emerges rapidly during therapy. Proposed mediators of platinum resistance include the protein kinase C (PKC) signal transduction pathway and associated c-FOS overexpression. While...

journal_title：Cancer chemotherapy and pharmacology

authors： Lara PN Jr,Gandara DR,Longmate J,Gumerlock PH,Lau DH,Edelman MJ,Gandour-Edwards R,Mack PC,Israel V,Raschko J,Frankel P,Perez EA,Lenz HJ,Doroshow JH

更新日期：2001-07-01 00:00:00

abstract：:Ankinomycin is a new antitumor antibiotic found in the culture broth of Streptomyces sp. SF2587. Ankinomycin showed marked cytotoxicity and antitumor activity against some murine leukemias, but the activity against murine solid tumors was rather weak because of its strong acute toxicity. We synthesized ankinomycin acy...

journal_title：Cancer chemotherapy and pharmacology

authors： Ishii S,Satoh Y,Tsuruo T

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:The aim of this study was to determine the usefulness of receptor occupancy theory-based analysis using pharmacokinetic and pharmacodynamic parameters for predicting the average receptor occupancy (PhiB) in humans of each of five 5-HT3 antagonists administered at standard doses. METHODS:The relationship betwee...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamada Y,Sugiura M,Higo K,Ozeki T,Takayanagi R,Okuyama K,Yamamoto K,Satoh H,Sawada Y,Iga T

更新日期：2004-08-01 00:00:00

abstract：:Selective protection of the normal host tissues from the toxic effects of anticancer agents would allow the use of higher, probably more effective, doses of the drugs. It has been demonstrated that delayed high-dose uridine administration after 5-fluorouracil decreases the extent of myelosuppression and causes faster ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kralovanszky J,Prajda N,Kerpel-Fronius S,Bagrij T,Kiss E,Peters GJ

更新日期：1993-01-01 00:00:00

abstract：:The novel anticancer compound GR63178A is being evaluated in the clinic, having demonstrated activity against a wide range of experimental tumour systems in animals without significant toxic side-effects being apparent. In this work, we have demonstrated significant antitumour action of this compound against one murin...

journal_title：Cancer chemotherapy and pharmacology

authors： French RC,Cummings J,MacLellan A,MacPherson JS,Ritchie AA,Smyth JF

更新日期：1993-01-01 00:00:00

abstract：:Peripheral blood stem and progenitor cells (PBSC and PBPC), which circulate at very low levels during steady-state hematopoiesis, show a transient but marked increase during hematologic recovery from marrow-suppressive chemotherapy. To ensure rapid and sustained hematologic engraftment after autologous PBSC transplant...

journal_title：Cancer chemotherapy and pharmacology

authors： Harada M,Teshima T,Fujisaki T,Mizuno S,Miyamoto T,Takamatsu Y,Kubota A,Ohno Y,Kuroiwa M,Takenaka K,Eto T,Akashi K,Gondo H,Okamura T,Inaba S,Niho Y

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:The aim of this study was to evaluate a phenotypic cell panel with tumor cells from various patients and normal cells for preclinical profiles of antitumor efficacy and toxicity of anticancer drugs. METHODS:The antitumor activity of fourteen anticancer drugs was tested in over one hundred tumor samples from pa...

journal_title：Cancer chemotherapy and pharmacology

authors： Haglund C,Aleskog A,Nygren P,Gullbo J,Höglund M,Wickström M,Larsson R,Lindhagen E

更新日期：2012-03-01 00:00:00

abstract：PURPOSE:Thyroid cancers with unsatisfactory curative effect nowadays are the most common malignant tumors of the endocrine system. Apoptosis evasion, a hallmark of cancer, has driven the search of stimulating novel cell death way in cancer therapy. This review aims to explore the relationship between autophagy and thyr...

journal_title：Cancer chemotherapy and pharmacology

authors： Li LC,Liu GD,Zhang XJ,Li YB

更新日期：2014-03-01 00:00:00

abstract：PURPOSE:Cancer, a major public health problem, exhibits significant redox alteration. Thioredoxin (Trx) system, including Trx and Trx reductase (TrxR), as well as Trx-interacting protein (TXNIP) play important roles in controlling the cellular redox balance in cancer cells. In most cancers, Trx and TrxR are usually ove...

journal_title：Cancer chemotherapy and pharmacology

authors： Jia JJ,Geng WS,Wang ZQ,Chen L,Zeng XS

更新日期：2019-09-01 00:00:00

abstract：PURPOSE:Capecitabine is a prodrug that undergoes metabolism in three steps to form an active 5-fluorouracil (5-FU). The first step is primarily catalyzed by liver carboxylesterases (CES) 1. Here, we examined the effects of CES1 variants on pharmacokinetics and toxicity of capecitabine. METHODS:We enrolled postoperativ...

journal_title：Cancer chemotherapy and pharmacology

authors： Matsumoto N,Kubota Y,Ishida H,Sekido M,Ohkuma R,Ishiguro T,Hirasawa Y,Ariizumi H,Tsunoda T,Ikusue T,Kobayashi K,Hisamatsu A,Toshima H,Shimada K,Fujita KI

更新日期：2020-06-01 00:00:00

abstract：PURPOSE:Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1-3, approved for second-line treatment of advanced renal cell carcinoma (RCC). Preclinical studies did not indicate potential for axitinib-induced delayed cardiac repolarization. METHODS:The effect of axitinib on corr...

journal_title：Cancer chemotherapy and pharmacology

authors： Ruiz-Garcia A,Houk BE,Pithavala YK,Toh M,Sarapa N,Tortorici MA

更新日期：2015-03-01 00:00:00

abstract：:We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines. DDH belongs to a family of aldoketo reductases that are involved in the detoxifica...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen J,Adikari M,Pallai R,Parekh HK,Simpkins H

更新日期：2008-05-01 00:00:00

abstract：PURPOSE:Platinum-based chemotherapy is the recognized first-line treatment for metastatic nasopharyngeal carcinoma (NPC). However, no standard treatment regimens have been established. This phase II study was designed to evaluate the efficacy and safety of a paclitaxel, cisplatin and 5-FU combination in metastatic and/...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen C,Wang FH,An X,Luo HY,Wang ZQ,Liang Y,Zhang L,Li YH

更新日期：2013-02-01 00:00:00

abstract：PURPOSE:To compare the response, survival, hematological and non-hematological toxicities of gemcitabine administrated at fixed-dose rate infusion (10 mg/m(2)/min, FDR) and standard 30 min infusion in patients with advanced non-small-cell lung cancer (NSCLC). METHODS:Electronic databases of MEDLINE, EMBASE and Cochran...

journal_title：Cancer chemotherapy and pharmacology

authors： Qiu MT,Ding XX,Hu JW,Tian HY,Yin R,Xu L

更新日期：2012-12-01 00:00:00

abstract：:Severe, debilitating nausea and vomiting are seen in almost 100% of patients treated with cis-platinum. These side-effects can be so severe and prolonged as to preclude therapy in a large number of patients. Commonly used antiemetics have had only limited success in controlling cis-platinum-induced nausea and vomiting...

journal_title：Cancer chemotherapy and pharmacology

authors： Aapro MS,Alberts DS

更新日期：1981-01-01 00:00:00